Cold bone defect on granulocytes labelled with technetium-99m-HMPAO scintigraphy: significance and usefulness for diagnosis and follow-up of osteoarticular infections

Scand J Infect Dis. 2004;36(3):209-12. doi: 10.1080/00365540310018851.

Abstract

We wished to determine the frequency and significance of cold bone defect on granulocytes labelled with technetium-99-m-hexamethylpropyleneamine oxime (99mTc-HMPAO-PMN) in non-spinal bone infection. Cold bone defect was investigated as part of a retrospective review during a 2-y period. Patients who had possible osteoarticular infection underwent bone scintigraphy combined with 99mTc-HMPAO-PMN for diagnosis and follow-up. Osteomyelitis was confirmed by isolation of the responsible pathogen. Among 210 patients who had possible infection, 17 (8%) demonstrated a cold bone defect. The site of cold bone defect was for all patients the hip. All 17 patients had proven bacterial orthopaedic hardware-related infection. The single causative micro-organism was staphylococcus. Whatever the outcome, cold bone defect was constant regardless of follow-up equal to or longer than 18 months. These data suggest that this uncommon scintigraphic pattern is an indication of an infectious process similar to increased uptake.

Publication types

  • Comparative Study
  • Evaluation Study

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Arthritis, Reactive / diagnosis
  • Arthritis, Reactive / diagnostic imaging*
  • Arthritis, Reactive / mortality
  • Arthritis, Reactive / therapy
  • Bone and Bones / diagnostic imaging*
  • Female
  • Follow-Up Studies
  • Granulocytes
  • Humans
  • Image Enhancement / methods
  • Male
  • Middle Aged
  • Osteomyelitis / diagnosis
  • Osteomyelitis / diagnostic imaging*
  • Osteomyelitis / mortality
  • Osteomyelitis / therapy
  • Prosthesis-Related Infections / diagnosis
  • Prosthesis-Related Infections / diagnostic imaging*
  • Prosthesis-Related Infections / mortality
  • Prosthesis-Related Infections / therapy
  • Radionuclide Imaging
  • Retrospective Studies
  • Risk Assessment
  • Sensitivity and Specificity
  • Severity of Illness Index
  • Survival Rate
  • Technetium Tc 99m Exametazime*
  • Treatment Outcome

Substances

  • Technetium Tc 99m Exametazime